| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Topline Data Readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Endocrine System | ||
Topline Data Readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Endocrine System | ||
Topline Data Readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Endocrine System |
Recent Updates
Recently added Catalysts
OmniAb, Inc. Common Stock$2.24
+0.37 (+18.23%)
Market Cap
324.74 M
EPS
-0.37
P/E Ratio
-
Value Trade
1.03 M
SEC Financials
Q1 2026Dilution Risk
Revenue
14.43 M
R&D Expenses
9.64 M
Operating CF
-4.91 M
Total Assets
293.65 M
Total Liabilities
31.00 M
Equity
262.65 M
12.56 %
Week
-3.45 %
1 Month
52.38 %
3 Month
35.76 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
49.07 M
Monthly Burn
1.64 M
Runway
27 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
700.54 K
52 Week Range
1.30 - 2.79
% held by Insiders
18.54 %
% held by Institutions
47.42 %
Enterprise Value
275.67 M
Total Shares
144.92 M
Short %
4.98 %
Float Shares
74.78 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for OmniAb, Inc. Common Stock
193Total events
1Upcoming
66Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 1
TBD
T1Topline Readout
Subscribe to view catalyst details
Event history 2
TBD
◆Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in OABI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
OABI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-OABI
Aug 6, 2026▲ +18.2%today
OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights
OmniAb, Inc. has reported its financial results for Q2 2026, showcasing a strong performance with increased revenue and an optimistic cash outlook for the year. The company highlighted ongoing progress in its operating and partner programs, reflecting positive business momentum. This update suggests a favorable trajectory for OmniAb as it advances its discovery research technology.
Read more →-OABI
Jul 16, 2026OmniAb to Report Second Quarter 2026 Financial Results on August 6
OmniAb, Inc. has announced that it will report its financial results for the second quarter of 2026 on August 6. The report will cover the three and six months ending June 30, 2026, and will be followed by a conference call at 4:30 p.m. Eastern time. This event reflects the company's commitment to keeping investors informed.
Read more →-OABI
Jul 13, 2026▼ -7.9%on this newsshared move
OmniAb Names Amechi Nwachuku Chief Operating Officer
OmniAb, Inc. has appointed Amechi Nwachuku as the new Chief Operating Officer. This newly-created position aims to enhance the strategy and operations of the company's proprietary technology, xPloration®. Nwachuku's appointment is expected to drive commercial success and innovation within the organization.
Read more →-OABI
May 7, 2026OmniAb Reports First Quarter 2026 Financial Results and Business Highlights
OmniAb has reported its financial results for the first quarter of 2026, along with key business highlights. The article provides insights into the company's performance and strategic initiatives during this period. However, specific details regarding financial metrics and business developments are not disclosed in the provided text.
Read more →-OABI
Apr 24, 2026▼ -6.4%on this news
OmniAb to Participate in Three Upcoming Investor Conferences
OmniAb, Inc. (NASDAQ: OABI) will participate in three upcoming investor conferences. The events include a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on May 6, one-on-one meetings at the Benchmark 6th Annual Healthcare House Call Virtual Investor Conference on May 28, and a corporate overview at the Jefferies Global Healthcare Conference from June 2-4. These engagements highlight the company's commitment to investor relations.
Read more →-OABI
Apr 21, 2026OmniAb to Report First Quarter 2026 Financial Results on May 7
OmniAb, Inc. will announce its financial results for Q1 2026 on May 7, 2026, after market close. A conference call will follow at 4:30 p.m. Eastern time to discuss these results and provide business updates. The company is known for its advanced discovery technology in the biopharma sector.
Read more →-OABI
Mar 5, 2026▲ +10.5%on this news
OmniAb Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
OmniAb, Inc. reported its financial results for Q4 and the full year of 2025, showing a decline in revenue and an increase in net loss compared to 2024. The company highlighted its expanding partner base and the launch of its new technology, OmniUltra™, while also providing financial guidance for 2026. Despite the challenges, OmniAb remains optimistic about its future growth prospects.
Read more →-OABI
Nov 4, 2025OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights Conference Call with Slides Begins at 4 30 p.m. Eastern Time Today EMERYVILLE, Calif. (
OmniAb, Inc. reported its financial results for Q3 and the first nine months of 2025, revealing a decline in revenue but an increase in the number of new programs and partnerships. The company plans to launch its OmniUltra technology in December 2025, which could unlock further business opportunities. Despite a consistent net loss compared to the previous year, OmniAb strengthened its balance sheet through a private placement in August. As of September 30, 2025, the company's cash and equivalents stood at $59.5 million, with expectations for revenue in 2025 estimated between $18 million and $22 million.
Read more →-OABI
Aug 25, 2025▼ -11.9%on this news
OmniAb Announces $30 Million Private Placement EMERYVILLE, Calif. (
OmniAb, Inc. has announced a definitive securities purchase agreement to raise approximately $30 million through a private placement of common stock. The company will issue 21,254,106 shares at a price of $1.40 per share, with officer and director participation priced at $1.85 per share. The net proceeds are intended for general corporate purposes, and the closing is expected to occur on August 26, 2025, pending customary closing conditions. Leerink Partners is acting as the sole placement agent for this financing.
Read more →-OABI
Aug 6, 2025▼ -5.4%on this news
OmniAb Reports Second Quarter 2025 Financial Results and Business Highlights Conference Call with Slides Begins at 4 30 p.m. Eastern Time Today EMERYVILLE, Calif. (
OmniAb, Inc. reported its financial results for Q2 2025, highlighting the addition of six new license agreements and achieving 100 active partners. However, revenue fell to $3.9 million in Q2 2025, down from $7.6 million in Q2 2024, contributing to a net loss of $15.9 million. The company's recent initiatives include the launch of the xPloration Partner Access Program and a strong focus on innovation amidst operational adjustments.
Read more →-OABI
May 8, 2025OmniAb Reports First Quarter 2025 Financial Results and Business Highlights Conference Call with Slides Begins at 4 30 p.m. Eastern Time Today EMERYVILLE, Calif. (
OmniAb, Inc. reported its financial results for Q1 2025, showing a revenue increase to $4.2 million. The company has initiated several new partnerships and programs aimed at advancing its technology. Despite a continued net loss of $18.2 million, OmniAb affirmed its 2025 revenue guidance and reduced its operating expense projections. The launch of the xPloration Partner Access Program is meant to enhance business opportunities and increase scalability of their technology platforms.
Read more →-OABI
Mar 18, 2025OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights Conference Call with Slides Begins at 4 30 p.m. Eastern Time Today EMERYVILLE, Calif. (
OmniAb, Inc. reported its financial results for the fourth quarter and full year of 2024, showcasing a notable increase in revenue for Q4 compared to the same time in 2023. The CEO highlighted substantial growth in active partners and clinical programs, alongside the launch of the OmniHub data interface. However, the total revenue for 2024 declined relative to 2023 due to previous milestone payments. The company also anticipates lower cash use and provided financial guidance for 2025, expecting revenue between $20 million and $25 million.
Read more →-OABI
Nov 12, 2024OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights Conference Call with Slides Begins at 4 30 p.m. Eastern Time Today EMERYVILLE, Calif. (
OmniAb, Inc. reported its financial results for the third quarter of 2024, showing a revenue decline to $4.2 million from $5.5 million in the same period last year. Despite this, the company noted growth in its technology platform and expanding partnership portfolio, reaching 86 active partners. The net loss for the quarter increased slightly to $16.4 million and the company expects operating expenses to remain lower than in 2023. Additionally, OmniAb is well-capitalized, having a cash balance projected between $50 million and $60 million by year-end 2024.
Read more →-OABI
Aug 8, 2024▲ +5.7%on this news
OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights Conference Call with Slides Begins at 4 30 p.m. Eastern Time Today EMERYVILLE, Calif. (
OmniAb, Inc. reported its financial results for Q2 2024, showcasing a revenue increase to $7.6 million compared to $6.9 million in Q2 2023. Despite a reduction in net losses, the overall revenue for the first half of 2024 decreased significantly compared to the previous year. The company also highlighted progress in partnerships and business development, suggesting a positive outlook for deal flow in the coming year. OmniAb's current cash position is expected to support operations adequately in the near future.
Read more →-OABI
May 9, 2024OmniAb Reports First Quarter 2024 Financial Results and Business Highlights Conference Call with Slides Begins at 4 30 p.m. Eastern Time Today EMERYVILLE, Calif. (
OmniAb, Inc. reported its financial results for Q1 2024, highlighting a decrease in revenue to $3.8 million from $16.9 million in the same quarter of 2023. The increase in net loss to $19 million reflects ongoing expenses as the company continues to invest in research and development. Despite these challenges, OmniAb announced the addition of three new platform partners, bringing its total to 80. The company maintains expectations for continued growth in 2025, supported by its current cash reserve of $69 million.
Read more →-OABI
Mar 20, 2024OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights Conference Call with Slides Begins at 4 30 p.m. Eastern Time Today EMERYVILLE, Calif. (
OmniAb, Inc. reported its financial results for Q4 and the full year of 2023, revealing a notable decline in revenue to $4.8 million for Q4, down from $35.3 million in 2022. Despite the challenges, the company achieved a significant expansion in its partnerships, with six new programs entering clinics. The operating losses increased alongside expenses, but OmniAb is optimistic about future growth, expecting operating expenses to remain stable in 2024. The company also launched two new technologies aimed at enhancing its development capabilities.
Read more →-OABI
Nov 9, 2023OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights Webcast including Research Technology Event begins at 11 00 a.m. Eastern time today EMERYVILLE, Calif. (
OmniAb, Inc. (OABI) announced its financial results for Q3 2023, reporting a revenue of $5.5 million, a decline from $6.9 million in Q3 2022. Despite the revenue dip, the company has added three new partners, bringing its total active programs to 314. The net loss increased to $15.7 million compared to $12.6 million in the previous year. The firm is focusing on technology innovation and is hosting a Research Technology virtual event to showcase its advancements.
Read more →-OABI
Aug 10, 2023OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights Conference Call with Slides Begins at 4 30 p.m. Eastern Time Today EMERYVILLE, Calif. (
OmniAb, Inc. reported its second quarter 2023 financial results, highlighting a revenue of $6.9 million and an expansion of its partner programs. Notably, the company added four new partners, with total active programs reaching 305, two of which entered clinical trials. However, the net loss widened to $14.7 million compared to the same quarter last year. The company also anticipates spending levels to remain elevated due to increased operational costs.
Read more →-OABI
May 11, 2023OmniAb Reports First Quarter 2023 Financial Results and Business Highlights Conference Call with Slides Begins at 8 30 a.m. Eastern Time Today EMERYVILLE, Calif. (
OmniAb, Inc. reported a strong start to 2023 with first-quarter financial results showing a revenue increase to $16.9 million. The company announced the advancement of its diverse portfolio of programs, now totaling 301, including 27 in clinical development. OmniAb also highlighted the upcoming launch of its OmniDeep platform, designed to facilitate rapid candidate identification for drug development, enhancing collaboration with partners. The management is set to discuss these results further in a conference call today.
Read more →-OABI
Mar 30, 2023OmniAb Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights Conference Call with Slides Begins at 4 30 p.m. Eastern Time Today EMERYVILLE, Calif. (
OmniAb, Inc. has announced its financial results for Q4 and the full year 2022. The company reported a revenue of $35.3 million in Q4, significantly up from $15.3 million in the same period of 2021, driven by a milestone payment from TECVAYLI. OmniAb added 13 new partnerships in 2022 and expects continued cash flow support from recent milestone payments. The company looks ahead to introducing new technologies and strengthening its antibody discovery capabilities as an independent entity following its spin-off from Ligand Pharmaceuticals.
Read more →-OABI
Jan 9, 2023We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of ope
OmniAb, Inc. has issued a cautionary notice regarding forward-looking statements related to its business strategy and technology platform. The company highlights the inherent uncertainties faced in biopharmaceutical development, including reliance on market acceptance and the unpredictable nature of regulatory approvals. It notes a significant addressable market for antibodies, projected to reach $279 billion by 2025, while also detailing the risks associated with economic fluctuations and the dependence on partner collaborations. Overall, the firm is poised for growth but acknowledges the challenges ahead in its operational landscape.
Read more →-OABI
Nov 15, 2022▼ -10%on this news
OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights EMERYVILLE, Calif. (
OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights EMERYVILLE, Calif. (November 15, 2022) OmniAb, Inc. (NASDAQ: OABI) reported financial results for the three and nine months ended September 30, 2022 and provided operating and program updates. OmniAb wa
Read more →-OABI
Nov 7, 2022▼ -5.6%on this news· ran to +40% by day 3
have the same meaning as terms defined and included elsewhere in the Current Report on Form 8-K filed with the Securities and Exchange Commission on
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Defined terms included below and not otherwise defined in this Exhibit 99.1 have the same meaning as terms defined and included elsewhere in the Current Report on Form 8-K filed with the Securities and Exchange Commis
Read more →-OABI
Jun 21, 2022Analyst Teach - In
Analyst Teach - In June 21, 2022 11 am EDT 2 LEGAL DISCLAIMERS About this Presentation This presentation is for informational purposes only to assist interested parties in making their own evaluation with respect to a proposed business combination (the Business Combination) betw
Read more →-OABI
Mar 23, 2022Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II Transaction will result in OmniAb becoming an independent publicly traded company Ligand's shareholders to receive 100% of Lig
Ligand to Spin-Off its OmniAb Business Through Avista Public Acquisition Corp. II Transaction will result in OmniAb becoming an independent publicly traded company Ligand's shareholders to receive 100% of Ligand's shares in OmniAb through a tax-free distribution immediately
Read more →-OABI
Jan 28, 2022AVISTA PUBLIC ACQUISITION CORP. II INDEX TO FINANCIAL STATEMENT Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of
AVISTA PUBLIC ACQUISITION CORP. II INDEX TO FINANCIAL STATEMENT Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of August 12, 2021 (As Restated) F-3 Notes to Financial Statement (As Restated) F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTIN
Read more →-OABI
Sep 30, 2021Avista Public Acquisition Corp. II Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing
Avista Public Acquisition Corp. II Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing September 30, 2021 NEW YORK, NY, September 27, 2021 - Avista Public Acquisition Corp. II (the "Company") announced that commencing September 30, 2021, hold
Read more →-OABI
Aug 9, 2021Avista Public Acquisition Corp. II Announces Pricing of $200 Million Initial Public Offering
Avista Public Acquisition Corp. II Announces of $200 Million Initial Public Offering NEW YORK, NY--(BUSINESS WIRE)--Avista Public Acquisition Corp. II (the "Company"), a special purpose acquisition company formed for the purpose of entering into a combination with one or more
Read more →Competitive Position
How OABI ranks across every disease it competes inCompetitive Position is a premium feature
See how OABI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial